Peptable

Comparison

BPC-157 vs Sermorelin

Function

While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Sermorelin is used as a diagnostic agent for assessing GH secretory capacity and as a research tool or off-label therapy to increase endogenous GH in GH-deficient or age-related contexts1727.

Mechanism

While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Sermorelin is a synthetic 29-amino-acid peptide identical to the 1–29 N-terminal fragment of human GHRH that stimulates GH synthesis and secretion by binding pituitary GHRH receptors1727120.

Receptor

BPC-157

VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11

Sermorelin

Growth hormone–releasing hormone receptor (GHRHR) on pituitary somatotrophs94103120

Organism or Origin

BPC-157

Synthetic peptide derived from a naturally occurring human gastric 'Body Protection Compound' isolated from human gastric juice111

Sermorelin

Synthetic peptide corresponding to human hypothalamic GHRH(1–29) 17120

Gene

BPC-157

Not assigned in the current dataset.

Sermorelin

GHRH

Summary

BPC-157 and Sermorelin are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas Sermorelin is more often associated with the realm of Metabolic and endocrine and Aging and longevity. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas Sermorelin is a receptor agonist. Both are synthetic in origin and their development context also differs, with BPC-157 in Preclinical development while Sermorelin is approved. Sermorelin incorporates amidation features that are not part of BPC-157, while their sequence patterns also diverge, with BPC-157 showing proline-rich features and Sermorelin showing alpha-helical domain features.

Sources

11BPC-157 - Wikipedia, https://en.wikipedia.org/wiki/BPC-157
17Sermorelin - Wikipedia, https://en.wikipedia.org/wiki/Sermorelin
27Sermorelin, https://pubchem.ncbi.nlm.nih.gov/compound/Sermorelin
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone